Navigation Links
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Date:11/17/2010

function (){ cf_jq(".cf_pushbutton_activate").live("mouseover", function (){ //Omniture Link Tracking Code /*var s=s_gi(s_account); s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.prop16='CrowdFactory_Share'; s.tl(this,'o', 'CrowdFactory_Share');*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='108672374';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='108672374';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

A second AHA presentation includes mouse model data showing plaque reduction.

TSX Exchange Symbol: RVX CHICAGO, Nov. 17 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)  announces its top line results of the ASSERT Phase 2 clinical trial which will be highlighted at the prestigious American Heart Association Scientific Sessions 2010 Late Breaking Clinical Trial session, by principal investigator Dr. Stephen Nicholls of the Cleveland Clinic. The top line ASSERT trial data was designed to answer questions about how to best proceed with future trial designs for Resverlogix' lead oral small molecule drug RVX-208.

The ASSERT trial data demonstrated t
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
2. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
3. Resverlogixs Phase 2 ASSURE Trial Amended
4. Resverlogix Scientific Data Presented at EAS Congress
5. Resverlogix Completes Dosing for ASSERT Trial
6. Resverlogix Notice of Conference Call & Webcast for Year End Update
7. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
8. Resverlogix Completes Patient Recruitment for ASSERT Trial
9. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
10. Resverlogix Presenting at Biotech Showcase
11. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 According to ... Sera, Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen ... Clinical Trials), End User - Global Forecast to 2020", ... to reach USD 3,731.03 Million by 2020 from USD ... 11.65% between 2015 and 2020. Browse ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City ... firms and animal health companies to hear from animal health companies with the ... also received licensing agreements or distribution contracts. This meeting is one of ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... - Engineers at Rensselaer Polytechnic Institute have developed tools to ... of stem cell research how to quickly test stem ... create a large supply of healthy, viable stem cells to ... have created methods to study millions of stems cells on ...
... to discover life on Mars were successfully launched into ... experiment to assess their survivability in the space radiation ... approach is based on technology similar to that used ... in the Life Marker Chip (LMC) experiment, which has ...
... engineers often deal with the same problems, but they ... other can be difficult, if not impossible., A new ... by the National Science Foundation (NSF), will help bridge ... to solve common problems a range of scientists face., ...
Cached Biology Technology:Putting stem cell research on the fast track 2Putting stem cell research on the fast track 3Putting stem cell research on the fast track 4Life on Mars 'pregnancy test' successfully launched 2CCMR gets $2.9M for training grad students in nanoscale science 2
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... problem, there is a greater risk that you will consume ... Sahlgrenska Academy, at the University of Gothenburg, Sweden. ,It ... likely to have a drink problem in the future, and ... on this link. Carried out by researcher Anna Sderpalm Gordh, ...
... of Energy,s (DOE) Brookhaven National Laboratory and collaborators at the ... where to insert a double bond when desaturating plant fatty ... amino acid far from the enzyme,s active site solves ... control. The work, published in the Proceedings of the ...
... SuviCa Inc. of Boulder and the University of Colorado ... drug screening technology to identify novel therapies for cancer. ... CU-Boulder Associate Professor Tin Tin Su of the molecular, ... Drosophila fruit fly model to screen for compounds effective ...
Cached Biology News:Scientists solve long-standing plant biochemistry mystery 2Scientists solve long-standing plant biochemistry mystery 3Scientists solve long-standing plant biochemistry mystery 4SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology 2
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... For applications not requiring confocal, the BD ... to the Pathway 435. And, the Pathway ... later applications require it. ... elect to use the laser autofocus, camera ...
... Blot includes 7 ... isolated from Alzheimer's-diseased brain ... postcentral gyrus, frontal lobe, ... occipital lobe and cerebellum. ...
... The Agilent One-Color RNA Spike-In Kit ... specifically anneal only to complementary control probes ... cross-hybridization. The spike-ins serve as a positive ... NOTE: This kit is a ...
Biology Products: